For example, one approach currently in phase 1 clinical trial is the use of a neutralizing antibody targeting LINGO-1 since antagonism of LINGO-1 promotes OPC differentiation and leads to remyelination in mouse models of MS (Mi et al., 2007, 2009, 2013). This evidence concerns the gene LINGO1 and myeloid sarcoma.